{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'One or more occurrences of an event that is not commonly associated with drug', 'exposure, but is otherwise uncommon in the population exposed to the drug (e.g., tendon', 'rupture).', 'An aggregate analysis of specific events observed in a clinical trial (such as known', 'consequences of the underlying disease or condition under investigation or other events', 'that commonly occur in the study population independent of drug therapy) that indicates', 'those events occur more frequently in the drug treatment group than in a concurrent or', 'historical control group.', '9.5.4.1.5 Reporting and Documenting SAEs', 'All SAEs beginning with the time of signing of the ICF and continuing until 30 days after study', 'discharge must be reported. The following steps will be taken to report promptly and document', 'accurately any SAE, whether or not it appears to be related to the study medication:', '1. Report the SAE to the Sponsor by entering the information in the eCRF within', '24 hours after becoming aware that a subject has experienced an SAE. If unable to', 'access the eCRF, the event must be reported by submitting the completed SAE form', 'by email to', 'fax, or telephone within 24 hours', 'after becoming aware that a subject has experienced an SAE (see Appendix 17.1 for', 'contact information).', '2. Perform appropriate diagnostic tests and therapeutic measures, and submit all follow-', 'up substantiating data, such as diagnostic test reports, hospital discharge summaries,', \"and autopsy report to the Sponsor's representative.\", '3. Respond in a timely manner to any queries from Sponsor regarding the SAE.', '4. Conduct appropriate consultation and follow-up evaluation until the SAE is resolved,', 'stabilized, or otherwise explained by the Investigator.', '5. Review each SAE report and evaluate the relationship of the SAE to study treatment.', 'The Sponsor will determine whether the SAE is unexpected in nature.', '6. The Investigator must report all AEs or SAEs that meet the criteria for Unanticipated', 'Problems Involving Risks to Human Subjects or Others to the IRB/IEC.', '9.5.4.1.6 Follow-Up of Adverse Events', 'Any ongoing study drug-related AE present at the time of study termination, including a', 'clinically significant laboratory test abnormality, will be followed until resolved or until the', 'event stabilizes and the overall clinical outcome has been ascertained.', 'In the event of unexplained, treatment-emergent, clinically significant abnormal laboratory test', 'results or clinically significant changes in laboratory test results, the tests should be repeated', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 89 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'immediately and followed until the values have returned to within the reference range or to', 'Baseline for that subject.', '9.5.4.1.7 Medication Error and Overdose', 'An overdose is defined as a known deliberate or accidental administration of investigational', 'drug, to, or by a study subject, at a dose > 5% above that which is assigned to that individual', 'subject according to the study protocol.', 'All cases of medication errors and overdose (with or without associated AEs) will be', 'documented on the eCRF in order to capture this important safety information consistently in the', 'database. AEs associated with an overdose and SAEs of overdose are to be reported according to', 'the procedures outlined in Sections 9.5.4.1.2 and 9.5.4.1.5, respectively.', 'In the event of drug overdose, the subject is to be treated with symptomatic and supportive care', 'as required.', '9.5.4.1.8 Review of Adverse Events and Emerging New Safety Information', 'The Sponsor will perform an ongoing review of all AEs and all other emerging new information', 'relevant to the safety of the drug, including periodic review and analyses of their entire safety', 'database.', '9.5.4.1.9 Reporting of IND Safety Reports', 'The Sponsor will notify the US FDA and all Investigators on any new serious risks associated', 'with the drug.', '9.5.4.1.10 Reporting of Suspected Unexpected Serious Adverse Reactions in the EU', 'The Sponsor or designee will report all Suspected Unexpected Serious Adverse Reactions', '(SUSARs), to the competent authorities and the concerned ethics committee according to', 'applicable law. Investigators will also be informed according to local requirements.', '9.5.4.1.11 Development Safety Update Reports', 'The Sponsor will prepare and submit annual safety reports to competent authorities and', 'concerned ethics committees.', '9.5.4.2 Pregnancy Reporting', 'Urine pregnancy testing will be performed for women of childbearing potential (including those', 'with an onset of menopause <2 years prior to Screening of HZNP-TEP-301, non-therapy-', 'induced amenorrhea for <12 months prior to Screening of HZNP-TEP-301, or not surgically', 'sterile [absence of ovaries and/or uterus]) at all clinic visits. Urinary pregnancy tests will be', 'performed locally.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 90 of 118']\n\n###\n\n", "completion": "END"}